Abstract Library

#3274 hPG80 (Circulating Progastrin), a novel blood-based biomarker for detection of well-differentiated neuroendocrine tumors

Introduction: Current blood-based biomarkers for neuroendocrine tumors (NETs) lack both sensitivity and specificity. Human circulating progastrin (hPG80) is a novel biomarker for NETs and is easily measured in plasma using an ELISA test.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Chauhan A, Prieur A, Kolesar J, Arnold S, Cousin T,

Keywords: neuroendocrine tumor, progastrin, hPG80, blood-based biomarker,

#78 The diagnostic and prognostic value of elevated proGRP levels in well- and moderately differentiated neuroendocrine tumors

Introduction: Chromogranin A (CgA) is the most frequently used marker in well- (grade 1) and moderately (grade 2) differentiated NETs. Although CgA is a more sensitive marker than the 5-HIAA, which was widely used until the last decade, CgA has some limitations. False-positively elevated CgA may occur in renal impairment, atrophic gastritis and during treatment of proton-pump inhibitors. Progastrin-releasing peptide (proGRP) was recently reported as a promising tumor marker for small cell lung cancer. Limited data suggests that ProGRP may be a potential tumor marker in NE tumors.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Korse C, Bonfrer J, van den Heuvel M, van Velthuysen M, Vincent A,

Keywords: Well- and moderately differentiated neuroendocrine tumors, proGastrin Releasing Peptide, chromogranin A, lung tumors,